NCT02401165

Brief Summary

GADD34 is an inducible cofactor of protein phosphatase 1, which has an important role in the Unfolded Protein Response (UPR). UPR is a cellular response to ER stress which is implicated in several autoimmune diseases. GADD34 has been shown to be necessary for proinflammatory cytokine production in response to viral infection in murine models. Nevertheless, the role of GADD34 in cytokine production in humans remains to be elucidated. Here, we investigate the interest of GADD34 in rheumatoid arthritis (RA), in which proinflammatory cytokines have an important pathogenic role. A case-control study on GADD34 gene expression in PBMC of patients (n=75) with RA and age- and sex-matched healthy controls (n=25). GADD34 gene expression levels in PBMC were measured by quantitative PCR.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100

participants targeted

Target at P50-P75 for not_applicable rheumatoid-arthritis

Timeline
Completed

Started Mar 2013

Shorter than P25 for not_applicable rheumatoid-arthritis

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2013

Completed
1.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2014

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2014

Completed
11 months until next milestone

First Submitted

Initial submission to the registry

March 24, 2015

Completed
3 days until next milestone

First Posted

Study publicly available on registry

March 27, 2015

Completed
Last Updated

March 27, 2015

Status Verified

March 1, 2015

Enrollment Period

1.2 years

First QC Date

March 24, 2015

Last Update Submit

March 24, 2015

Conditions

Keywords

GADD34Unfolded Protein ResponseAnti-citrullinated protein antibodies

Outcome Measures

Primary Outcomes (1)

  • To determine if GADD34 gene expression level in the PBMC of rheumatoid arthritis patients is increased compared to its expression in the PBMC of healthy controls.

    GADD34 gene expression level is quantified in the PBMC by quantitative PCR.

    3 years

Secondary Outcomes (4)

  • To verify the repeatability and reproducibility of GADD34 gene expression quantification by quantitative PCR.

    3 years

  • To compare GADD34 gene expression level in the PBMC of 3 groups of patients: patients with DAS28<2.6 (low RA activity), DAS28>2.6 and <5.1 (intermediate RA activity), DAS28>5.1 (high RA activity).

    3 years

  • GADD34 gene expression in synovial cells.

    3 years

  • GADD34 and cytokine production.

    3 years

Study Arms (1)

patient

OTHER

patient

Other: Blood test

Interventions

blood test

patient

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • patients with rheumatoid arthritis fulfilling the American College of Rheumatology 1987 revised criteria for the classification of RA
  • age between 18 and 75
  • patients benefiting of social security
  • Informed consent signed by the patients
  • groups of patients were included: patients with DAS28\<2.6 (n=25); patients with DAS28\>2.6 and\<5.1 (n=25): patients with DAS28\>5.1 (n=25).

You may not qualify if:

  • patients who receive treatments for other pathologies
  • persons protected by the law L1121-5 to L1121-8 of CSP (for example: pregnant women)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (1)

  • Clavarino G, Adriouach S, Quesada JL, Clay M, Chevreau M, Trocme C, Grange L, Gaudin P, Gatti E, Pierre P, Cesbron JY, Dumestre-Perard C. Unfolded protein response gene GADD34 is overexpressed in rheumatoid arthritis and related to the presence of circulating anti-citrullinated protein antibodies. Autoimmunity. 2016;49(3):172-8. doi: 10.3109/08916934.2016.1138220. Epub 2016 Feb 1.

MeSH Terms

Conditions

Arthritis, Rheumatoid

Interventions

Hematologic Tests

Condition Hierarchy (Ancestors)

ArthritisJoint DiseasesMusculoskeletal DiseasesRheumatic DiseasesConnective Tissue DiseasesSkin and Connective Tissue DiseasesAutoimmune DiseasesImmune System Diseases

Intervention Hierarchy (Ancestors)

Clinical Laboratory TechniquesDiagnostic Techniques and ProceduresDiagnosisInvestigative Techniques

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
BASIC SCIENCE
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 24, 2015

First Posted

March 27, 2015

Study Start

March 1, 2013

Primary Completion

May 1, 2014

Study Completion

May 1, 2014

Last Updated

March 27, 2015

Record last verified: 2015-03